A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

Conditions

• Adults With Overweight/Obesity and Type 2 Diabetes

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• AT673 low dose — DRUG
  low dose
• AT673 high dose — DRUG
  high dose
• Placebo — DRUG
  matching placebo

Study Details

The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes. The main questions it aims to answer are: * To compare the effect on body weight of two doses of AT673 once-weekly versus matched placebo when concurrently administered with semaglutide once-weekly * To evaluate the effect of AT673 on glycated hemoglobin (HbA1c) * To compare the safety and tolerability of AT673 versus matched placebo when concurrently administered with semaglutide

Key Dates

First listed

Jul 24, 2026

Start date

Jun 19, 2026

Status verified

Jul 2026

Primary completion

Feb 28, 2027

Completion

Mar 31, 2027

Study Design

Enrollment

150 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Low dose
  Low dose AT673, subcutaneous injection administered weekly
• Experimental: High dose
  High dose AT673 subcutaneous injection administered weekly
• Placebo Comparator: Placebo
  matching placebo subcutaneous injection administered weekly

Primary Outcome Measure

Body weight [ Time Frame: 13 weeks ]

Locations (8)

Find similar trials in Chandler, AZ